EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study

Giorgio Tiecco iD, Angelica Lenzi iD, Federico Cesanelli iD, Evelyn Van Hauwermeiren, Francesco Rossini iD, Alessio Sollima iD, Alice Mulé, Silvia Lorenzotti, Liana Signorini, Francesco Castelli iD, Eugenia Quiros-Roldan iD

Antibiotics · 26.06.2026 · 15 (7) · 640

DOI: 10.3390/antibiotics15070640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 26.06.2026. Verfasst von Giorgio Tiecco und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia,…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dalbavancin (DBV) is a long-acting lipoglycopeptide with activity against Gram-positive pathogens approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Its pharmacological profile supports use in infections requiring prolonged therapy, yet its role in osteomyelitis without implantable devices (OM-WoID) remains off-label. This study aims to describe real-world DBV use in a large tertiary care hospital, focusing on its effectiveness in OM-WoID.

Methods

This is a monocentric, retrospective analysis including all patients receiving DBV at ASST Spedali Civili di Brescia, Italy, from April 2017 to July 2023. The statistical analysis focused on patients who received DBV for either ABSSSI or OM-WoID, with the latter transitioning to DBV after traditional daily intravenous therapy. Clinical, microbiological, and treatment data were extracted from electronic records and stored in REDCap. Effectiveness was defined as infection resolution or improvement; treatment failure encompassed clinical worsening, recurrence or suppressive therapy. Predictors of failure were identified through univariate and stepwise multivariate logistic regression.

Results

During the study period, 157 patients (63.0% male; mean age 62.5 ± 20 years) received at least one dose of DBV, predominantly for off-label indications (66.2%). Early discharge was the most common reason for switching to DBV (66.3%). Focusing specifically on patients treated for ABSSSI (53) and OM-WoID (43), treatment success was achieved in 81.1% of ABSSSI and 90.7% of OM-WoID cases. In the stepwise multivariate logistic regression, older age was independently associated with an increased risk of treatment failure (OR 1.07, 95% CI 1.01–1.13; p = 0.028), while the presence of multimorbidity significantly reduced the risk (OR 0.07, 95% CI 0.01–0.77; p = 0.029).

Discussion

Our study offers a comprehensive real-world analysis of DBV use in both approved and off-label indications. Although current clinical experience with DBV remains limited, DBV emerges as a valuable step-down option for the management of invasive Gram-positive infections in our setting. Consistent with previous evidence, older age independently increased the risk of treatment failure, whereas multimorbidity appeared protective, likely due to selection bias and the more intensive monitoring, earlier interventions, and tailored management such patients often receive. Our results support a broader range of approved indications for DBV to allow earlier discharge and more efficient use of healthcare resources.

Schlagwörter

Stichwörter der Autor:innen

Gram positivedalbavancinimplantable devicesoff-labelosteomyelitis

Autor:innen und Institutionen

  • Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
  • Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
  • Department of Global Public Health, Karolinska Institute, 17177 Stockholm, Sweden.

ORCID-Profile: Giorgio Tiecco, Angelica Lenzi, Federico Cesanelli, Francesco Rossini, Alessio Sollima, Francesco Castelli, Eugenia Quiros-Roldan

Zitieren

APA

Tiecco, G., Lenzi, A., Cesanelli, F., Van Hauwermeiren, E., Rossini, F., Sollima, A., Mulé, A., Lorenzotti, S., Signorini, L., Castelli, F., & Quiros-Roldan, E. (2026). Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study. Antibiotics, 15(7), 640. https://doi.org/10.3390/antibiotics15070640

Vancouver

Tiecco G, Lenzi A, Cesanelli F, Van Hauwermeiren E, Rossini F, Sollima A, et al. Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study. Antibiotics. 2026;15(7):640. doi:10.3390/antibiotics15070640

BibTeX
@article{Tiecco2026,
  author = {Tiecco, Giorgio and Lenzi, Angelica and Cesanelli, Federico and Van Hauwermeiren, Evelyn and Rossini, Francesco and Sollima, Alessio and Mulé, Alice and Lorenzotti, Silvia and Signorini, Liana and Castelli, Francesco and Quiros-Roldan, Eugenia},
  title = {Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {640},
  doi = {10.3390/antibiotics15070640}
}
Kostenlos starten →